The APOBEC3B cytidine deaminase is an adenovirus restriction factor.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
27
09
2022
accepted:
26
01
2023
revised:
16
02
2023
pubmed:
7
2
2023
medline:
22
2
2023
entrez:
6
2
2023
Statut:
epublish
Résumé
Human adenoviruses (HAdVs) are a large family of DNA viruses counting more than a hundred strains divided into seven species (A to G). HAdVs induce respiratory tract infections, gastroenteritis and conjunctivitis. APOBEC3B is a cytidine deaminase that restricts several DNA viruses. APOBEC3B is also implicated in numerous cancers where it is responsible for the introduction of clustered mutations into the cellular genome. In this study, we demonstrate that APOBEC3B is an adenovirus restriction factor acting through a deaminase-dependent mechanism. APOBEC3B introduces C-to-T clustered mutations into the adenovirus genome. APOBEC3B reduces the propagation of adenoviruses by limiting viral genome replication, progression to late phase, and production of infectious virions. APOBEC3B restriction efficiency varies between adenoviral strains, the A12 strain being more sensitive to APOBEC3B than the B3 or C2 strains. In A12-infected cells, APOBEC3B clusters in the viral replication centers. Importantly, we show that adenovirus infection leads to a reduction of the quantity and/or enzymatic activity of the APOBEC3B protein depending on the strains. The A12 strain seems less able to resist APOBEC3B than the B3 or C2 strains, a characteristic which could explain the strong depletion of the APOBEC3-targeted motifs in the A12 genome. These findings suggest that adenoviruses evolved different mechanisms to antagonize APOBEC3B. Elucidating these mechanisms could benefit the design of cancer treatments. This study also identifies adenoviruses as triggers of the APOBEC3B-mediated innate response. The involvement of certain adenoviral strains in the genesis of the APOBEC3 mutational signature observed in tumors deserves further study.
Identifiants
pubmed: 36745676
doi: 10.1371/journal.ppat.1011156
pii: PPATHOGENS-D-22-01680
pmc: PMC9934312
doi:
Substances chimiques
Cytidine Deaminase
EC 3.5.4.5
Proteins
0
Minor Histocompatibility Antigens
0
APOBEC3B protein, human
EC 3.5.4.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1011156Informations de copyright
Copyright: © 2023 Lejeune et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Virol. 2010 Oct;84(19):10402-5
pubmed: 20660203
J Biol Chem. 2011 Oct 21;286(42):36427-37
pubmed: 21878639
J Virol. 2021 Nov 9;95(23):e0117021
pubmed: 34523960
PLoS Pathog. 2020 Aug 14;16(8):e1008718
pubmed: 32797103
Curr Top Microbiol Immunol. 2004;273:215-44
pubmed: 14674603
Oncogene. 2022 Apr;41(15):2139-2151
pubmed: 35194151
Microorganisms. 2020 Nov 30;8(12):
pubmed: 33266042
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4858-63
pubmed: 21368204
Cancer Discov. 2021 Oct;11(10):2456-2473
pubmed: 33947663
Cell Rep. 2014 Jun 26;7(6):1833-41
pubmed: 24910434
Virology. 2005 Sep 1;339(2):281-8
pubmed: 15993456
J Gen Virol. 2005 Jan;86(Pt 1):125-129
pubmed: 15604439
Sci Rep. 2019 Jun 5;9(1):8307
pubmed: 31165764
mBio. 2014 Dec 23;5(6):
pubmed: 25538195
PLoS Pathog. 2016 May 03;12(5):e1005621
pubmed: 27137912
Sci Adv. 2016 Oct 07;2(10):e1601737
pubmed: 27730215
Nat Microbiol. 2019 Jan;4(1):78-88
pubmed: 30420783
mBio. 2019 Feb 5;10(1):
pubmed: 30723127
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6
pubmed: 15919829
Clin Microbiol Rev. 2014 Jul;27(3):441-62
pubmed: 24982316
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Virol. 1980 Jan;33(1):423-37
pubmed: 7365869
Virus Evol. 2015 Jan;1(1):
pubmed: 27570633
PLoS One. 2013 Sep 20;8(9):e75208
pubmed: 24073254
J Virol. 2019 Nov 13;93(23):
pubmed: 31534038
J Virol. 2012 Jun;86(11):6097-108
pubmed: 22457529
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
J Virol. 2017 Sep 27;91(20):
pubmed: 28794024
Mol Ther Oncolytics. 2018 Aug 29;11:1-13
pubmed: 30294666
J Virol. 2016 Jun 24;90(14):6379-6386
pubmed: 27147740
Transl Res. 2021 Nov;237:1-15
pubmed: 34004371
J Virol. 2017 Feb 28;91(6):
pubmed: 28077648
Cell Host Microbe. 2018 May 9;23(5):628-635.e7
pubmed: 29746834
EMBO J. 1982;1(1):79-86
pubmed: 7188179
Nat Genet. 2015 Sep;47(9):1067-72
pubmed: 26258849
Cancer Res. 2015 Nov 1;75(21):4538-47
pubmed: 26420215
Nature. 2013 Feb 21;494(7437):366-70
pubmed: 23389445
J Virol. 2011 Jun;85(11):5701-2
pubmed: 21450823
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32870257
Cancer Res. 2004 Dec 15;64(24):9027-34
pubmed: 15604268
Nat Rev Genet. 2022 Aug;23(8):505-518
pubmed: 35256818
J Virol. 2011 Jan;85(2):765-75
pubmed: 21068234
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nucleic Acids Res. 2006 Jan 10;34(1):89-95
pubmed: 16407327
J Virol. 2021 Jun 10;95(13):e0241320
pubmed: 33853956
Semin Respir Crit Care Med. 2016 Aug;37(4):586-602
pubmed: 27486739
MMWR Morb Mortal Wkly Rep. 2017 Oct 06;66(39):1039-1042
pubmed: 28981484
Nat Genet. 2013 Sep;45(9):977-83
pubmed: 23852168
Elife. 2013 Apr 16;2:e00534
pubmed: 23599896
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Science. 2014 Oct 10;346(6206):251-6
pubmed: 25301630
PLoS Pathog. 2018 Jan 11;14(1):e1006717
pubmed: 29324878
Nucleic Acids Res. 2010 Jul;38(13):4274-84
pubmed: 20308164
J Microsc. 1993 Mar;169(3):375-382
pubmed: 33930978